logo
Plus   Neg
Share
Email

Moderna Announces Investment To Increase Global Manufacturing Capacity For COVID-19 Vaccine

Moderna Inc. (MRNA) Wednesday said it is making new capital investments to increase capacity at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to about 1.4 billion doses of its COVID-19 vaccine.

The investments will enable additional production of the current Moderna COVID-19 vaccine.

The company has already begun adding this capacity at its owned and partnered manufacturing facilities.

"We believe from our discussions with governments around the world that there will continue to be significant demand for our COVID-19 vaccine and we now are committed to materially increasing our manufacturing capacity. Because of the high efficacy of our COVID-19 vaccine and our ability to quickly develop variant vaccines to help boost the immune system of vaccinees, there is increased demand. We are investing in this additional capacity to help us increase production and allow for flexibility in manufacturing potential vaccine boosters to address emerging variants of the virus," said CEO Stephane Bancel.

Moderna also announces it is increasing its base plan for 2021 manufacturing from 600 million doses to 700 million doses globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Performance Food Group Co. announced Tuesday its agreement to acquire Core-Mark Holding Co., Inc., a wholesale distributor to the convenience retail industry, in around $2.5 billion stock and cash transaction, including net debt. In pre-markey activity on Nasdaq, Core-Mark shares were gaining around 9 percent to trade at $45.86. Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2022 that declined 31.6 percent from last year, hurt by net losses on equity investments, However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The retailer also raised its guidance for the second quarter and for the full-year 2022. European Medicines Agency or EMA announced that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech, can have more flexible storage conditions, including up to one month in a normal fridge. The proposed change in the approved storage conditions, recommended by EMA's human medicines committee or CHMP, will help in easy handling of the vaccine in vaccination centres across the EU.
Follow RTT